Nicholas Cammack, Head of Snakebite
Nick leads the Snakebite programme and also the Covid-19 Therapeutics Accelerator which was initiated at the start of the pandemic as part of Wellcome’s emergency response.
Nick joined Wellcome in 2019 to lead the Snakebite programme – an £80 million fund to drive a step-change in snakebite treatment around the world. Since March 2020 Nick also leads Wellcome’s activities in Covid-19 therapeutics. He is a member of the UK Government’s Antiviral Task Force and leads an R&D cooperation of international partners to ensure Covid-19 treatments reach everyone who needs them around the world.
Previously, Nick was Head of the GSK Tres Cantos Medicines Development Campus for Diseases of the Developing World in Madrid, Spain. In this role, he was responsible for the discovery and development of medicines to treat some of the most devastating neglected diseases including malaria, tuberculosis, Chagas disease and Leishmaniasis. Nick led the drug discovery through an open innovation agenda of collaboration with many organisations such as Medicines for Malaria Venture, Global Alliance for TB, Drugs for Neglected Diseases Initiative, Wellcome Trust and the Bill & Melinda Gates Foundation.
Of note, Nick established and implemented the Tres Cantos Open Lab Foundation (TCOLF) – a not-for-profit foundation that supports academic scientists to visit GSK in Tres Cantos to pursue their own drug discovery ideas, taking advantage of the expertise and facilities available there. This is a first for the Pharma industry and continues to be viewed as a bold, innovative step in neglected tropical disease drug discovery.